Developed & Manufactured by Biomedica

Human Periostin ELISA | BI-20433

Cat. No.: BI-20433

1 kit / €  675,00Please Inquire

Contact distributor

Human Periostin ELISA highlights:
Therapeutic Areas
Periostin protein structure
Human Periostin ELISA typical standard curve
human Periostin levels in control, asthma and cardiology cohorts
Assay Characteristics
  • Method

    Sandwich ELISA, HRP/TMB, 12×8-well detachable strips

  • Sample type

    Serum, plasma (EDTA, citrate, heparın), urine, cell culture supernatant

  • Sample volume

    10 µl / well

  • Assay time

    2 h / 2 h / 1 h / 30 min

  • Sensitivity

    20 pmol/l (= 1 800 pg/ml)

  • Standard range

    0 – 4 000 pmol/l (= 0 – 360 000 pg/ml)

  • Conversion factor

    1 pmol/l = 91 pg/ml (MW: 91 kDa)

  • Specificity

    Endogenous and recombinant human Periostin; all known isofoms.

  • Precision

    In-between-run (n=10): ≤ 6 % CV

    Within-run (n=5): ≤ 3 % CV

  • Cross-reactivity

    Due to the high sequence homology between human Periostin and Periostin of other species there is potential cross-reactivity with cynomolgous monkey, dog and cat Periostin.

  • Use

    Research use only

  • Validation Data

    See validation data tab for: precision, accuracy, dilution linearity, values for healthy donors, etc

Product details

Human Periostin ELISA Product Overview

The human Periostin ELISA kit is a 5.5 hour, 96-well sandwich ELISA for the quantitative determination of Periostin in human serum and plasma. The Periostin assay employs human serum-based standards to ensure the measurement of biologically reliable data.

The human Periostin kit uses highly purified, epitope mapped antibodies with characterized binding kinetics.

Human Periostin ELISA Assay Principle

The Periostin ELISA kit human is a sandwich enzyme immunoassay for the quantitative determination of periostin in human serum and plasma samples.

The figure below explains the principle of the Periostin ELISA:

Human Periostin ELISA kit assay priniciple

Capture antibody: monoclonal mouse anti-human Periostin antibody
Detection antibody: polyclonal goat anti-human Periostin antibody, biotin labeled
Target antigen: human Periostin

In a first step, pre-diluted standard/control/sample and biotinylated polyclonal goat anti-human Periostin antibody are pipetted into the wells of the microtiter strips, which are pre-coated with mouse monoclonal anti-human Periostin antibody. Periostin present in the standard/control/sample binds to the pre-coated antibody in the well and forms a sandwich with the detection antibody. In a washing step all non-specific unbound material is removed. In a second step, the conjugate (streptavidin-HRP) is pipetted into the wells and reacts with the detection antibody. After another washing step, the substrate (TMB, tetramethylbenzidine) is pipetted into the wells. The enzyme-catalyzed color change of the substrate is directly proportional to the amount of Periostin present in the sample. This color change is detectable with a standard microtiter plate reader. A dose response curve of the absorbance (optical density, OD at 450 nm) vs. standard concentration is generated, using the values obtained from the standard. The concentration of human Periostin in the sample is determined directly from the dose response curve.

Human Periostin ELISA Typical Standard Curve

The figure below shows a typical standard curve for the human Periostin ELISA. The immunoassay is calibrated against recombinant human Periostin peptide:

Human Periostin ELISA kit Typical standard curve

Human Periostin ELISA Kit Components

Contents Description Quantity

PLATE

 Monoclonal mouse anti-human Periostin antibody pre-coated microtiter strips in a strip holder, packed in an aluminum bag with desiccant 12 x 8 tests
WASHBUF

Wash buffer concentrate 20x, natural cap

 1 x 50 ml
STD Standards 1-7, (0, 125, 250, 500, 1000, 2000, 4000 pmol/l), recombinant human Periostin in human serum, white caps, lyophilized 7 vials
CTRL Control A and B, yellow cap, lyophilized, exact concentrations see labels 2 vials
ASYBUF Assay buffer, red cap, ready to use 1 x 55 ml
AB Polyclonal goat anti-human Periostin antibody – biotin labeled, green cap, ready to use 1 x 18 ml
CONJ

Conjugate (streptavidin-HRP), amber bottle, amber cap, ready to use

 1 x 18 ml
SUB

Substrate (TMB solution), amber bottle, blue cap, ready to use

 1 x 22 ml
STOP

Stop solution, white cap, ready to use

 1 x 7 ml

Storage instructions: All reagents of the human Periostin ELISA kit are stable at 4°C (2-8°C) until the expiry date stated on the label of each reagent.

Instructions for use

Sample Collection & Storage

Serum, EDTA plasma, heparın plasma, citrate plasma, urine and cell culture supernatant are suitable for use in this Periostin assay. Do not change sample type during studies. We recommend duplicate measurements for all samples, standards and controls. The sample collection and storage conditions listed are intended as general guidelines.

Serum & Plasma

Collect venous blood samples in standardized serum separator tubes (SST) or standardized blood collection tubes using EDTA, heparın or citrate as an anticoagulant. For serum samples, allow samples to clot for 30 minutes at room temperature. Perform separation by centrifugation according to the tube manufacturer’s instructions for use. Assay the acquired samples immediately or aliquot and store at -25°C or lower. Lipemic or haemolyzed samples may give erroneous results. Samples are stable for four freeze-thaw cycles. Thawed samples should be assayed as soon as possible. 

Urine

Note: the experiments performed to measure Periostin in urine samples did not undergo a full validation according to FDA/ICH/EMEA guidelines. However, our performance check suggests that urine samples can be measured with this ELISA.

Aseptically collect the first urine of the day (mid-stream), voided directly into a sterile container. Centrifuge to remove particulate matter, assay immediately or aliquot and store at -25°C or lower. Do not freeze-thaw samples more than four times. Thawed samples should be assayed as soon as possible.

Cell Culture Supernatant

Note: the experiments performed to measure Periostin cell culture supernatant samples did not undergo a full validation according to FDA/ICH/EMEA guidelines. However, our performance check suggests that cell culture supernatant samples can be measured with this ELISA. 

Remove particulates by centrifugation and assay immediately or aliquot and store samples at
-25°C or lower. Do not freeze-thaw samples more than four times. Thawed samples should be assayed as soon as possible.

Reagent Preparation

Wash Buffer

1. Bring the WASHBUF concentrate to room temperature (18-26°C). Crystals in the buffer concentrate will dissolve at room temperature.
2. Dilute the WASHBUF concentrate 1:20, e.g. 50 ml WASHBUF + 950 ml distilled or deionized water. Only use diluted WASHBUF when performing the assay.

The diluted WASHBUF is stable up to one month at 4°C (2-8°C).

Standards & Controls

1. Pipette 200 µl of distilled or deionized water into each standard (STD) and control (CTRL)vial. The exact concentration is printed on the label of each vial.
2. Leave at room temperature (18-26°C) for 20 min. Vortex gently.

Reconstituted STDs and CTRLs are stable at -25°C or lower until expiry date stated on the label. STDs and CTRLs can undergo one freeze-thaw cycle.

STDs/CTRLs must be diluted 1+50 with ASYBUF (assay buffer) prior to the assay, e.g. 10 µl STD/CTRL + 500 µl ASYBUF. 

Note: 150 µl pre-diluted STD/CTRl is needed per well.

Sample Preparation

Bring samples to room temperature and mix samples gently to ensure the samples are homogenous. We recommend duplicate measurements for all samples.

Serum and plasma samples must be diluted 1+50 with ASYBUF (assay buffer) prior to the assay, e.g. 10 µl sample + 500 µl ASYBUF. 1+50 diluted serum and plasma samples for which the OD still exceeds the highest point of the standard range can be further diluted with ASYBUF.

Note: 150 µl pre-diluted sample is required per well.

Use urine and cell culture supernatant samples undiluted. Urine and cell culture supernatant samples for which the OD exceeds the highest point of the standard range can be diluted 1+50 with ASYBUF (assay buffer).

Human Periostin ELISA Assay Protocol

Read the entire protocol before beginning the assay.

1. Bring samples and reagents to room temperature (18-26°C).
2. Mark positions for STD/CTRL/SAMPLE (standard/control/sample) on the protocol sheet.
3. Take microtiter strips out of the aluminum bag. Store unused strips with desiccant at 4°C in the aluminum bag. Strips are stable until expiry date stated on the label.
4. Add 150 µl pre-diluted (1+50) STD/CTRL/SAMPLE into the respective wells, swirl gently.

Note: use urine and cell culture supernatant samples undiluted.

5.

 Cover the plate tightly and incubate for 2 hours at room temperature (18-26°C).
6. Aspirate and wash wells 5 x with 300 µl diluted WASHBUF (wash buffer). After the final wash, remove the remaining WASHBUF by strongly tapping plate against a paper towel.
7. Add 150 µl AB (biotinylated anti-human Periostin antibody, green cap) into each well, swirl gently.
8. Cover tightly and incubate for 2 hours at room temperature.
9. Aspirate and wash wells 5 x with 300 µl diluted WASHBUF. After the final wash, remove the remaining WASHBUF by strongly tapping plate against a paper towel.
10. Add 150 µl CONJ (conjugate, amber cap) into each well. Swirl gently.
11. Cover tightly and incubate for 1 hour at room temperature.
12. Aspirate and wash wells 5 x with 300 µl diluted WASHBUF. After the final wash, remove the remaining WASHBUF by strongly tapping plate against a paper towel.
13. Add 150 µl SUB (substrate, blue cap) into each well.
14. Incubate for 30 min at room temperature in the dark.
15. Add 50 µl STOP (stop solution, white cap) into each well. Swirl gently.
16. Measure absorbance immediately at 450 nm with reference 630 nm, if available.

Calculation of Results

Construct a standard curve from the absorbance read-outs of the standards using commercially available software capable of generating a four-parameter logistic (4-PL) fit. Alternatively, plot the standards’ concentration on the x-axis against the mean absorbance for each standard on the y-axis and draw a best fit curve through the points on the graph. Curve fitting algorithms other than 4-PL have not been validated and will need to be evaluated by the user.

Obtain sample concentrations from the standard curve. If required, pmol/l can be converted into pg/ml by applying a conversion factor (1 pg/ml = 0.011 pmol/l (MW: 91 kDa)). Sample dilutions above 1+50 have to be considered when calculating the final concentration of the sample. For undiluted samples, divide values by 50 to obtain the final sample concentration.

The quality control (QC) protocol supplied with the kit shows the results of the final release QC for each kit lot at production date. Data for OD obtained by customers may differ due to various influences including the normal decrease of signal intensity throughout shelf life. However, this does not affect validity of results as long as an OD of 1.50 or higher is obtained for the standard with the highest concentration and the values of the CTRLs are within the target range (see labels).

Background & Therapeutic Areas

Periostin Protein

Periostin (OSF-2) is secreted as a 91 kDa homodimeric soluble extracellular matrix protein expressed in collagen-rich fibrous connective tissues. There are at least 7 isoforms of Periostin, caused by alternative splicing (http://www.uniprot.org/uniprot/Q15063).

Molecular weight

 91 kDa
Cellular localisation Extracellular or secreted
Post-translational modifications Glycosylation, disulphide bonds
Sequence similarities FAS1 superfamily
Alternative names POSTN, OSF-2, OSF2, PDLPN, PN
Pubchem ID 187888
Genecards POSTN
OMIM 608777
PDB 5WT7
5YJG
5YJH
Pfam PF02469
Protein Atlas POSTN
Uniprot ID Q15063

Periostin Function

Periostin is involved in osteoblast recruitment, attachment and spreading. It has been associated with the epithelial-mesenchymal transition in cancer and with the differentiation of mesenchyme in the developing heart. Periostin has functions in osteology, tissue repair, oncology, cardiovascular and respiratory diseases, and in various inflammatory settings.

  • Metabolic Disease

    Diabetic retinopathy (Ding et al., 2018)

  • Nephrology

    Kidney fibrosis (An et al., 2018; Hwang et al., 2017; Mael-Ainin et al., 2014; Sen et al., 2011)

    Polycystsic kidney disease (Raman et al., 2018; Wallace et al., 2014)

    Hypertensive nephropathy (Guerrot et al., 2012)

    Kidney injury (Satirapoj et al., 2015, 2014, 2012)

    IgA Nephrophathy (Hwang et al., 2016; Satirapoj et al., 2014)

  • Oncology

    Multiple myeloma (Terpos et al., 2016)

    Ameloblastoma (Kang et al., 2018)

    Ovarian cancer (Ryner et al., 2015; Sung et al., 2016; Tang et al., 2018)

    Papillary thyroid carcinoma (Giusca et al., 2017)

    Head and neck cancer (Liu et al., 2018)

    Breast carcinoma (Kim et al., 2017; Lambert et al., 2016; Nuzzo et al., 2016; Ratajczak-Wielgomas et al., 2017)

    Lung cancer (Che et al., 2017; Zhang et al., 2017)

    Osteosarcoma (Hu et al., 2016)

    Gastric cancer (Liu et al., 2016)

    Bladder cancer (Silvers et al., 2016)

    Prostate cancer (Tian et al., 2015)

  • Osteology

    Osteoporosis (Kim et al., 2015; Rousseau et al., 2014; Varughese et al., 2018; Yan et al., 2017)

    Paget’s disease (Polyzos et al., 2017)

    Osteoarthritis (Chijimatsu et al., 2015; Honsawek et al., 2015b; Rousseau et al., 2014; Tajika et al., 2017)

    Rheumatoid arthritis (Kerschan-Schindl et al., 2018; Sakellariou et al., 2015)

    Anyklosing spondylitis (Solmaz u. a., 2018)

  • Other

    Wound healing

    Miscarriage (Freis et al., 2017)

    Skin diseases (Murota et al., 2017; Sung et al., 2017)

    Liver stiffness (Honsawek et al., 2015)

  • Respitatory disease

    Asthma (Carpagnano et al., 2018; Górska et al., 2016; Hoshino et al., 2016; Inoue et al., 2016; Kim et al., 2014; Lee et al., 2018; Matsusaka et al., 2015; O’Dwyer and Moore, 2017; Song et al., 2015)

    Allergy (Fujishima et al., 2016; Izuhara et al., 2017)

    Pulmonary fibrosis (Ohta et al., 2017)

    Bronchopulmoany dysplasia (Ahlfeld et al., 2016)

Literature

Periostin Induces Kidney Fibrosis after Acute Kidney Injury via the p38 MAPK Pathway.
An, J.N., Yang, S.H., Kim, Y.C., Hwang, J.H., Park, J.Y., Kim, D.K., Kim, J.H., Kim, D.W., Hur, D.G., Oh, Y.K., Lim, C.S., Kim, Y.S., Lee, J.P., 2018. Am. J. Physiol. Renal Physiol.
PMID: 30539653

Looking for Airways Periostin in Severe Asthma: Could It Be Useful for Clustering Type 2 Endotype?
Carpagnano, G.E., Scioscia, G., Lacedonia, D., Soccio, P., Lepore, G., Saetta, M., Foschino Barbaro, M.P., Barnes, P.J., 2018. Chest 154, 1083–1090.
PMID: 30336944

Increased serum periostin concentrations are associated with the presence of diabetic retinopathy in patients with type 2 diabetes mellitus.
Ding, Y., Ge, Q., Qu, H., Feng, Z., Long, J., Wei, Q., Zhou, Q., Wu, R., Yao, L., Deng, H., 2018. J. Endocrinol. Invest. 41, 937–945.
PMID: 29349642

Upregulation of Periostin expression in the pathogenesis of ameloblastoma.
Kang, Y., Liu, J., Zhang, Y., Sun, Y., Wang, J., Huang, B., Zhong, M., 2018. Pathol. Res. Pract. 214, 1959–1965.
PMID: 30196986

Rheumatoid arthritis in remission : Decreased myostatin and increased serum levels of periostin.
Kerschan-Schindl, K., Ebenbichler, G., Föeger-Samwald, U., Leiss, H., Gesslbauer, C., Herceg, M., Stummvoll, G., Marculescu, R., Crevenna, R., Pietschmann, P., 2018. Wien. Klin. Wochenschr.
PMID: 30171335

Serum Periostin Levels: A Potential Serologic Marker for To luene Diisocyanate-Induced Occupational Asthma.
Lee, J.H., Kim, S.H., Choi, Y., Trinh, H.K.T., Yang, E.M., Ban, G.Y., Shin, Y.S., Ye, Y.M., Izuhara, K., Park, H.S., 2018. Yonsei Med. J. 59, 1214–1221.
PMID: 30450856; PMCID: PMC6240562

Bone marrow mesenchymal stem cells promote head and neck cancer progression through Periostin-mediated phosphoinositide 3-kinase/Akt/mammalian target of rapamycin.
Liu, C., Feng, X., Wang, B., Wang, X., Wang, C., Yu, M., Cao, G., Wang, H., 2018. Cancer Sci. 109, 688–698.
PMID: 29284199; PMCID: PMC5834805

Periostin overexpression in collecting ducts accelerates renal cyst growth and fibrosis in polycystic kidney disease.
Raman, A., Parnell, S.C., Zhang, Y., Reif, G.A., Dai, Y., Khanna, A., Daniel, E., White, C., Vivian, J.L., Wallace, D.P., 2018. Am. J. Physiol. Renal Physiol.
PMID: 30332313

Cross-talk between ovarian cancer cells and macrophages through periostin promotes macrophage recruitment.
Tang, M., Liu, B., Bu, X., Zhao, P., 2018. Cancer Sci. 109, 1309–1318.
PMID: 29527764; PMCID: PMC5980394

Serum periostin levels following small bone fractures, long bone fractures and joint replacements: an observational study.
Varughese, R., Semprini, R., Munro, C., Fingleton, J., Holweg, C., Weatherall, M., Beasley, R., Braithwaite, I., 2018. Allergy Asthma Clin. Immunol. Off. J. Can. Soc. Allergy Clin. Immunol. 14.
PMID: 30065761; PMCID: PMC6060508

Effects of lentivirus-mediated silencing of Periostin on tumor microenvironment and bone metastasis via the integrin-signaling pathway in lung cancer.
Che, J., Shen, W.-Z., Deng, Y., Dai, Y.-H., Liao, Y.-D., Yuan, X.-L., Zhang, P., 2017. Life Sci. 182, 10–21.
PMID: 28601389

Serum periostin levels in early in pregnancy are significantly altered in women with miscarriage.
Freis, A., Schlegel, J., Kuon, R.J., Doster, A., Jauckus, J., Strowitzki, T., Germeyer, A., 2017. Reprod. Biol. Endocrinol. RBE 15.
PMID: 29096644; PMCID: PMC5667517

Heterogeneous Periostin Expression in Different Histological Variants of Papillary Thyroid Carcinoma.
Giusca, S.E., Amalinei, C., Lozneanu, L., Ciobanu Apostol, D., Andriescu, E.C., Scripcariu, A., Balan, R., Avadanei, E.R., Căruntu, I.-D., 2017. BioMed Res. Int. 2017, 8701386.
PMID: 29435461; PMCID: PMC5757104

Experimental Inhibition of Periostin Attenuates Kidney Fibrosis.
Hwang, J.H., Yang, S.H., Kim, Y.C., Kim, J.H., An, J.N., Moon, K.C., Oh, Y.K., Park, J.Y., Kim, D.K., Kim, Y.S., Lim, C.S., Lee, J.P., 2017. Am. J. Nephrol. 46, 501–517.
PMID: 29268247

Periostin in inflammation and allergy.
Izuhara, K., Nunomura, S., Nanri, Y., Ogawa, M., Ono, J., Mitamura, Y., Yoshihara, T., 2017. Cell. Mol. Life Sci. CMLS 74, 4293–4303.
PMID: 28887633

Epithelial periostin expression is correlated with poor survival in patients with invasive breast carcinoma.
Kim, G.-E., Lee, J.S., Park, M.H., Yoon, J.H., 2017. PloS One 12, e0187635.
PMID: 29161296; PMCID: PMC5697858

Periostin in the pathogenesis of skin diseases.
Murota, H., Lingli, Y., Katayama, I., 2017. Cell. Mol. Life Sci. CMLS 74, 4321–4328.
PMID: 28916993

The role of periostin in lung fibrosis and airway remodeling.
O’Dwyer, D.N., Moore, B.B., 2017. Cell. Mol. Life Sci. CMLS 74, 4305–4314.
PMID: 28918442; PMCID: PMC5659879

The usefulness of monomeric periostin as a biomarker for idiopathic pulmonary fibrosis.
Ohta, S., Okamoto, M., Fujimoto, K., Sakamoto, N., Takahashi, K., Yamamoto, H., Kushima, H., Ishii, H., Akasaka, K., Ono, J., Kamei, A., Azuma, Y., Matsumoto, H., Yamaguchi, Y., Aihara, M., Johkoh, T., Kawaguchi, A., Ichiki, M., Sagara, H., Kadota, J.-I., Hanaoka, M., Hayashi, S.-I., Kohno, S., Hoshino, T., Izuhara, K., Consortium for Development of Diagnostics for Pulmonary Fibrosis Patients (CoDD-PF), 2017. PloS One 12, e0174547.
PMID: 28355256; PMCID: PMC5371347

Periostin and sclerostin levels in juvenile Paget’s disease.
Polyzos, S.A., Makras, P., Anastasilakis, A.D., Mintziori, G., Kita, M., Papatheodorou, A., Kokkoris, P., Terpos, E., 2017. Clin. Cases Miner. Bone Metab. Off. J. Ital. Soc. Osteoporos. Miner. Metab. Skelet. Dis. 14, 269–271.
PMID: 29263750; PMCID: PMC5726226

Expression of periostin in breast cancer cells.
Ratajczak-Wielgomas, K., Grzegrzolka, J., Piotrowska, A., Matkowski, R., Wojnar, A., Rys, J., Ugorski, M., Dziegiel, P., 2017. Int. J. Oncol. 51, 1300–1310.
PMID: 28902360

An association of periostin levels with the severity and chronicity of atopic dermatitis in children.
Sung, M., Lee, K.S., Ha, E.G., Lee, S.J., Kim, M.A., Lee, S.W., Jee, H.M., Sheen, Y.H., Jung, Y.H., Han, M.Y., 2017. Pediatr. Allergy Immunol. Off. Publ. Eur. Soc. Pediatr. Allergy Immunol. 28, 543–550.
PMID: 28631851

Influence of Periostin on Synoviocytes in Knee Osteoarthritis.
Tajika, Y., Moue, T., Ishikawa, S., Asano, K., Okumo, T., Takagi, H., Hisamitsu, T., 2017. Vivo Athens Greece 31, 69–77.
PMID: 28064223; PMCID: PMC5354150

Circulating periostin levels increase in association with bone density loss and healing progression during the early phase of hip fracture in Chinese older women.
Yan, J., Liu, H.J., Li, H., Chen, L., Bian, Y.Q., Zhao, B., Han, H.X., Han, S.Z., Han, L.R., Wang, D.W., Yang, X.F., 2017. Osteoporos. Int. J. Establ. Result Coop. Eur. Found. Osteoporos. Natl. Osteoporos. Found. USA 28, 2335–2341.
PMID: 28382553

Predictive and prognostic value of serum periostin in advanced non-small cell lung cancer patients receiving chemotherapy.
Zhang, Y., Yuan, D., Yao, Y., Sun, W., Shi, Y., Su, X., 2017. Tumour Biol. J. Int. Soc. Oncodevelopmental Biol. Med. 39, 1010428317698367.
PMID: 28459197

Early Elevation of Plasma Periostin Is Associated with Chronic Ventilator-Dependent Bronchopulmonary Dysplasia.
Ahlfeld, S.K., Davis, S.D., Kelley, K.J., Poindexter, B.B., 2016. Am. J. Respir. Crit. Care Med. 194, 1430–1433.
PMID: 27905846; PMCID: PMC5148145

The usefulness of measuring tear periostin for the diagnosis and management of ocular allergic diseases.
Fujishima, H., Okada, N., Matsumoto, K., Fukagawa, K., Igarashi, A., Matsuda, A., Ono, J., Ohta, S., Mukai, H., Yoshikawa, M., Izuhara, K., 2016. J. Allergy Clin. Immunol. 138, 459-467.e2.
PMID: 26964692

Comparative study of periostin expression in different respiratory samples in patients with asthma and chronic obstructive pulmonary disease.
Górska, K., Maskey-Warzęchowska, M., Nejman-Gryz, P., Korczyński, P., Prochorec-Sobieszek, M., Krenke, R., 2016. Pol. Arch. Med. Wewn. 126, 124–137.
PMID: 26895432

Association of airway wall thickness with serum periostin in steroid-naive asthma.
Hoshino, M., Ohtawa, J., Akitsu, K., 2016. Allergy Asthma Proc. 37, 225–230.
PMID: 27178891

High-level expression of periostin is significantly correlated with tumour angiogenesis and poor prognosis in osteosarcoma.
Hu, F., Shang, X.-F., Wang, W., Jiang, W., Fang, C., Tan, D., Zhou, H.-C., 2016. Int. J. Exp. Pathol. 97, 86–92.
PMID: 27028305; PMCID: PMC4840243

Urinary Periostin Excretion Predicts Renal Outcome in IgA Nephropathy.
Hwang, J.H., Lee, J.P., Kim, C.T., Yang, S.H., Kim, J.H., An, J.N., Moon, K.C., Lee, H., Oh, Y.K., Joo, K.W., Kim, D.K., Kim, Y.S., Lim, C.S., 2016. Am. J. Nephrol. 44, 481–492.
PMID: 27802442

Periostin as a biomarker for the diagnosis of pediatric asthma.
Inoue, T., Akashi, K., Watanabe, M., Ikeda, Y., Ashizuka, S., Motoki, T., Suzuki, R., Sagara, N., Yanagida, N., Sato, S., Ebisawa, M., Ohta, S., Ono, J., Izuhara, K., Katsunuma, T., 2016. Pediatr. Allergy Immunol. Off. Publ. Eur. Soc. Pediatr. Allergy Immunol. 27, 521–526.
PMID: 27062336

Tumor Cell-Derived Periostin Regulates Cytokines That Maintain Breast Cancer Stem Cells.
Lambert, A.W., Wong, C.K., Ozturk, S., Papageorgis, P., Raghunathan, R., Alekseyev, Y., Gower, A.C., Reinhard, B.M., Abdolmaleky, H.M., Thiagalingam, S., 2016. Mol. Cancer Res. MCR 14, 103–113.
PMID: 26507575; PMCID: PMC4715959

Isoprenaline Induces Periostin Expression in Gastric Cancer.
Liu, G.-X., Xi, H.-Q., Sun, X.-Y., Geng, Z.-J., Yang, S.-W., Lu, Y.-J., Wei, B., Chen, L., 2016. Yonsei Med. J. 57, 557–564.
PMID: 26996552; PMCID: PMC4800342

The prognostic value of stromal and epithelial periostin expression in human breast cancer: correlation with clinical pathological features and mortality outcome.
Nuzzo, P.V., Rubagotti, A., Zinoli, L., Salvi, S., Boccardo, S., Boccardo, F., 2016. BMC Cancer 16, 95.
PMID: 26872609; PMCID: PMC4752779

Identification of extracellular vesicle-borne periostin as a feature of muscle-invasive bladder cancer.
Silvers, C.R., Liu, Y.-R., Wu, C.-H., Miyamoto, H., Messing, E.M., Lee, Y.-F., 2016. Oncotarget 7, 23335–23345.
PMID: 26981774; PMCID: PMC5029630

Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung, P.-L., Jan, Y.-H., Lin, S.-C., Huang, C.-C., Lin, H., Wen, K.-C., Chao, K.-C., Lai, C.-R., Wang, P.-H., Chuang, C.-M., Wu, H.-H., Twu, N.-F., Yen, M.-S., Hsiao, M., Huang, C.-Y.F., 2016. Oncotarget 7, 4036–4047.
PMID: 26716408; PMCID: PMC4826188

High levels of periostin correlate with increased fracture rate, diffuse MRI pattern, abnormal bone remodeling and advanced disease stage in patients with newly diagnosed symptomatic multiple myeloma.
Terpos, E., Christoulas, D., Kastritis, E., Bagratuni, T., Gavriatopoulou, M., Roussou, M., Papatheodorou, A., Eleutherakis-Papaiakovou, E., Kanellias, N., Liakou, C., Panagiotidis, I., Migkou, M., Kokkoris, P., Moulopoulos, L.A., Dimopoulos, M.A., 2016. Blood Cancer J. 6, e482.
PMID: 27716740; PMCID: PMC5098262

Expression and pathological effects of periostin in human osteoarthritis cartilage.
Chijimatsu, R., Kunugiza, Y., Taniyama, Y., Nakamura, N., Tomita, T., Yoshikawa, H., 2015. BMC Musculoskelet. Disord. 16, 215.
PMID: 26289167; PMCID: PMC4545863

Elevated serum periostin is associated with liver stiffness and clinical outcome in biliary atresia.
Honsawek, S., Udomsinprasert, W., Vejchapipat, P., Chongsrisawat, V., Phavichitr, N., Poovorawan, Y., 2015a. Biomark. Biochem. Indic. Expo. Response Susceptibility Chem. 20, 157–161.
PMID: 25980529

Association of plasma and synovial fluid periostin with radiographic knee osteoarthritis: Cross-sectional study.
Honsawek, S., Wilairatana, V., Udomsinprasert, W., Sinlapavilawan, P., Jirathanathornnukul, N., 2015b. Jt. Bone Spine Rev. Rhum. 82, 352–355.
PMID: 25881760

Plasma periostin associates significantly with non-vertebral but not vertebral fractures in postmenopausal women: Clinical evidence for the different effects of periostin depending on the skeletal site. Kim, B.-J., Rhee, Y., Kim, C.H., Baek, K.H., Min, Y.-K., Kim, D.-Y., Ahn, S.H., Kim, H., Lee, S.H., Lee, S.-Y., Kang, M.-I., Koh, J.-M., 2015. Bone 81, 435–441.
PMID: 26297442

Phenotype of asthma related with high serum periostin levels.
Matsusaka, M., Kabata, H., Fukunaga, K., Suzuki, Y., Masaki, K., Mochimaru, T., Sakamaki, F., Oyamada, Y., Inoue, T., Oguma, T., Sayama, K., Koh, H., Nakamura, M., Umeda, A., Ono, J., Ohta, S., Izuhara, K., Asano, K., Betsuyaku, T., 2015. Allergol. Int. Off. J. Jpn. Soc. Allergol. 64, 175–180.
PMID: 25838094

Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer.
Ryner, L., Guan, Y., Firestein, R., Xiao, Y., Choi, Y., Rabe, C., Lu, S., Fuentes, E., Huw, L.-Y., Lackner, M.R., Fu, L., Amler, L.C., Bais, C., Wang, Y., 2015. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 21, 2941–2951.
PMID: 25838397

Circulating periostin levels in patients with AS: association with clinical and radiographic variables, inflammatory markers and molecules involved in bone formation.
Sakellariou, G.T., Anastasilakis, A.D., Bisbinas, I., Oikonomou, D., Gerou, S., Polyzos, S.A., Sayegh, F.E., 2015. Rheumatol. Oxf. Engl. 54, 908–914.
PMID: 25349442

Periostin as a tissue and urinary biomarker of renal injury in type 2 diabetes mellitus.
Satirapoj, B., Tassanasorn, S., Charoenpitakchai, M., Supasyndh, O., 2015. PloS One 10, e0124055.
PMID: 25884625; PMCID: PMC4401767

Serum periostin levels correlate with airway hyper-responsiveness to metha choline and mannitol in children with asthma.
Song, J.-S., You, J.-S., Jeong, S.-I., Yang, S., Hwang, I.-T., Im, Y.-G., Baek, H.-S., Kim, H.-Y., Suh, D.-I., Lee, H.-B., Izuhara, K., 2015. Allergy 70, 674–681.
PMID: 25703927

Overexpression of periostin in stroma positively associated with aggressive prostate cancer.
Tian, Y., Choi, C.H., Li, Q.K., Rahmatpanah, F.B., Chen, X., Kim, S.R., Veltri, R., Chia, D., Zhang, Z., Mercola, D., Zhang, H., 2015. PloS One 10, e0121502.
PMID: 25781169; PMCID: PMC4362940

Association of serum periostin with aspirin-exacerbated respiratory disease.
Kim, M.-A., Izuhara, K., Ohta, S., Ono, J., Yoon, M.K., Ban, G.Y., Yoo, H.-S., Shin, Y.S., Ye, Y.-M., Nahm, D.-H., Park, H.-S., 2014. Ann. Allergy Asthma Immunol. Off. Publ. Am. Coll. Allergy Asthma Immunol. 113, 314–320.
PMID: 25037608

Inhibition of Periostin Expression Protects against the Development of Renal Inflammation and Fibrosis.
Mael-Ainin, M., Abed, A., Conway, S.J., Dussaule, J.-C., Chatziantoniou, C., 2014. J. Am. Soc. Nephrol. 25, 1724–1736.
PMID: 24578131

Serum periostin is associated with fracture risk in postmenopausal women: a 7-year prospective analysis of the OFELY study.
Rousseau, J.C., Sornay-Rendu, E., Bertholon, C., Chapurlat, R., Garnero, P., 2014. J. Clin. Endocrinol. Metab. 99, 2533–2539.
PMID: 24628551

Urine Periostin as a Biomarker of Renal Injury in Chronic Allograft Nephropathy.
Satirapoj, B., Witoon, R., Ruangkanchanasetr, P., Wantanasiri, P., Charoenpitakchai, M., Choovichian, P., 2014. Transplant. Proc. 46, 135–140.

Periostin promotes renal cyst growth and interstitial fibrosis in polycystic kidney disease.
Wallace, D.P., White, C., Savinkova, L., Nivens, E., Reif, G.A., Pinto, C.S., Raman, A., Parnell, S.C., Conway, S.J., Fields, T.A., 2014. Kidney Int. 85, 845–854.
PMID: 24284511

Identification of periostin as a critical marker of progression/reversal of hypertensive nephropathy.
Guerrot, D., Dussaule, J.-C., Mael-Ainin, M., Xu-Dubois, Y.-C., Rondeau, E., Chatziantoniou, C., Placier, S., 2012. PloS One 7, e31974.
PMID: 22403621; PMCID: PMC3293874

Periostin: novel tissue and urinary biomarker of progressive renal injury induces a coordinated mesenchymal phenotype in tubular cells.
Satirapoj, B., Wang, Y., Chamberlin, M.P., Dai, T., LaPage, J., Phillips, L., Nast, C.C., Adler, S.G., 2012. Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc. 27, 2702–2711.
PMID: 22167593; PMCID: PMC3471549

Periostin Is Induced in Glomerular Injury and Expressed de Novo in Interstitial Renal Fibrosis.
Sen, K., Lindenmeyer, M.T., Gaspert, A., Eichinger, F., Neusser, M.A., Kretzler, M., Segerer, S., Cohen, C.D., 2011. Am. J. Pathol. 179, 1756–1767.
PMID: 21854746

Validation Data

All Biomedica ELISAs are validated according to international FDA/ICH/EMEA guidelines. For more information about our validation guidelines, please refer to our quality page and published validation guidelines and literature.

Show Validation Literature
  1. ICH Q2(R1) Validation of Analytical Procedures: Text and Methodology
  2. EMEA/CHMP/EWP/192217/2009 Guideline on bioanalytical method validation

Calibration

The human Periostin immunoassay is calibrated against recombinant human Periostin peptide.

Human Periostin ELISA Detection Limit & Sensitivity

To determine the sensitivity of the human Periostin ELISA, experiments measuring the lower limit of detection (LOD) and the lower limit of quantification (LLOQ) were conducted.

The LOD, also called the detection limit, is the lowest point at which a signal can be distinguished above the background signal, i.e. the signal that is measured in the absence of Periostin, with a confidence level of 99%. It is defined as the mean back calculated concentration a Periostin-free sample (three independent measurements) plus three times the standard deviation of the measurements.

The LLOQ, or sensitivity of an assay, is the lowest concentration at which an analyte can be accurately quantified. The criteria for accurate quantification at the LLOQ are an analyte recovery between 75 and 125% and a coefficient of variation (CV) of less than 25%. The lowest concentration of Periostin, which meets both criteria, is reported as the LLOQ.

The following values were determined for the human Periostin ELISA:

LOD 20 pmol/l
LLOQ 62.5 pmol/l

Human Periostin ELISA Precision

The precision of an ELISA is defined as its ability to measure the same concentration consistently within the same experiments carried out by one operator (within-run precision or repeatability) and across several experiments using the same samples but conducted by several operators using different ELISA lots (in-between-run precision or reproducibility).

Within-Run Precision

Within-run (intra-assay) precision was assessed by measuring two samples of known concentrations five times within one human Periostin ELISA lot by one operator.

ID n Mean Periostin [pmol/l] SD [pmol/l] CV (%)
Sample 1 5 249 7.3 3
Sample 2 5 2008 52 3

In-Between-Run Precision

In-between-run (inter-assay) precision was assessed by measuring two samples of known concentrations twelve times within multiple human Periostin ELISA lots by multiple operators.

ID n Mean Periostin [pmol/l]
 SD [pmol/l]
 CV (%)

Sample 1

10 251 11.2 4
Sample 2 10 1996 111.5 6

Human Periostin ELISA Accuracy

The accuracy of an ELISA is defined as the precision with which it can recover samples of known concentrations.

The recovery of the human Periostin ELISA was measured by adding recombinant Periostin to human samples containing a known concentration endogenous Periostin. The % recovery of the spiked concentration was calculated as the percentage of measured compared over the expected value.

This table shows the summary of the recovery experiments in the human Periostin ELISA in different sample matrices:

    % Recovery
    +500 pmol/l +2000 pmol/l
Sample matrix n Mean Range Mean Range
Serum 7 106 88 - 127 95 91 - 105
EDTA plasma 8 98 71 - 124 83 71 - 91
Heparın plasma 7 92 84 - 104 85 75 - 96
Citrate plasma 8 102 82 - 108 91 81 - 109
+ Show individual measurements

Data showing recovery of Periostin in human serum samples:

    Periostin [pmol/l] % Recovery
Sample matrix ID Reference +500 pmol/l +2000 pmol/l +500 pmol/l +2000 pmol/l
Serum s1 688 1044 2170 88 91
Serum s2 927 1251 2270 88 90
Serum s3 892 1417 2266 127 91
Serum s4 881 1257 2537 97 105
Serum s5 1138 1623 2500 126 97
Serum s6 1009 1471 2445 118 97
Serum s7 1107 1470 2437 100 94
        Mean 106 95
        Min 88 91
        Max 127 105

Data showing recovery of Periostin in human EDTA plasma samples:

    Periostin [pmol/l] % Recovery
Sample matrix ID Reference +500 pmol/l +2000 pmol/l +500 pmol/l +2000 pmol/l
EDTA plasma e1 907 1272 2266 96 91
EDTA plasma e2 542 1083 1980 122 85
EDTA plasma e3 774 1272 2021 119 82
EDTA plasma e4 784 1304 2187 124 90
EDTA plasma e5 789 1045 2321 71 96
EDTA plasma e6 1145 1356 2116 71 77
EDTA plasma e7 968 1256 1917 82 72
EDTA plasma e8 1008 1390 1921 102 71
        Mean 98 83
        Min 71 71
        Max 124 91

Data showing recovery of Periostin in human heparın plasma samples:

    Periostin [pmol/l] % Recovery
Sample matrix ID Reference +500 pmol/l +2000 pmol/l +500 pmol/l +2000 pmol/l
Heparın plasma h1 815 1201 2090 97 84
Heparın plasma h2 581 976 1878 94 79
Heparın plasma h3 765 1099 2090 86 85
Heparın plasma h4 808 1150 1908 89 75
Heparın plasma h5 831 1147 2345 84 96
Heparın plasma h6 780 1147 2067 93 84
Heparın plasma h7 998 1391 2304 104 90
        Mean 92 85
        Min 84 75
        Max 104 96

Data showing recovery of Periostin in human citrate plasma samples:

    Periostin [pmol/l] % Recovery
Sample matrix ID Reference +500 pmol/l +2000 pmol/l +500 pmol/l +2000 pmol/l
Citrate plasma c1 798 1181 2036 97 82
Citrate plasma c2 519 956 1852 100 80
Citrate plasma c3 671 1074 2009 97 84
Citrate plasma c4 707 1136 1978 103 81
Citrate plasma c5 702 1113 2535 100 109
Citrate plasma c6 904 1332 2569 108 106
Citrate plasma c7 914 1209 2278 82 91
Citrate plasma c8 829 1369 2256 129 92
        Mean 102 91
        Min 82 81
        Max 129 109

Human Periostin ELISA Dilution Linearity & Parallelism

Tests of dilution linearity and parallelism ensure that both endogenous and recombinant samples containing Periostin behave in a dose dependent manner and are not affected by matrix effects. Dilution linearity assesses the accuracy of measurements in diluted human samples spiked with known concentrations of recombinant analyte. By contrast, parallelism refers to dilution linearity in human samples and provides evidence that the endogenous analyte behaves the same way as the recombinant one. For dilution linearity and parallelism are assessed for each sample type and are considered acceptable if the results are within 20% of the expected concentration.

Dilution Linearity

Dilution linearity was assessed by serially diluting human samples spiked with 10 000 pmol/l recombinant human Periostin.

The table below shows the mean recovery serially diluted recombinant human Periostin in serum and citrate plasma. The reference value indicates the sample concentration before the spike.

    Periostin [pmol/l] % Recovery
Sample matrix ID Reference 1+4 1+9 1+4 1+9
Serum s1 1001 2342 1161 106 106
Serum s2 348 1765 956 85 92
Citrate plasma c1 665 1774 776 83 73
Citrate plasma c2 710 1918 858 90 80

Parallelism

Parallelism was assessed by serially diluting human samples containing endogenous Periostin with assay buffer.

The table below shows the mean recovery and range of serially diluted endogenous periostin in several human sample matrices:

    % Recovery of endogenous Periostin in diluted samples
    1+1 1+3
Sample matrix ID Mean Range Mean Range
Serum 12 101 90 - 113 105 69 - 134
EDTA plasma 4 99 97 - 101 115 110 - 117
Heparın plasma 4 96 92 - 97 126 104 - 177
Citrate plasma 4 95 92 - 101 122 117 - 124
Show individual measurements

Data showing dilution linearity of endogenous Periostin in human serum samples:

    Periostin [pmol/l] % Recovery
Sample matrix ID Reference 1+1 1+3 1+1 1+3
Serum s1 647 308 121 95 93
Serum s2 1280 725 302 113 118
Serum s3 372 186 53 100 72
Serum s4 953 488 199 102 105
Serum s5 1440 713 316 99 110
Serum s6 1466 754 307 103 105
Serum s7 603 284 83 94 69
Serum s8 837 375 154 90 92
Serum s9 1608 846 511 105 127
Serum s10 1612 860 540 107 134
Serum s11 1155 618 337 107 117
Serum s12 1359 691 395 102 116
        Mean 101 105
        Min 90 69
        Max 113 134

Data showing dilution linearity of endogenous Periostin in human EDTA plasma samples:

    Periostin [pmol/l] % Recovery
Sample matrix ID Reference 1+1 1+3 1+1 1+3
EDTA plasma e1 1468 714 431 97 117
EDTA plasma e2 1328 669 377 101 114
EDTA plasma e3 1222 614 359 100 117
EDTA plasma e4 1677 826 460 98 110
        Mean 99 115
        Min 97 110
        Max 101 117

Data showing dilution linearity of endogenous Periostin in human heparın plasma samples:

    Periostin [pmol/l] % Recovery
Sample matrix ID Reference 1+1 1+3 1+1 1+3
Heparın plasma h1 1031 500 268 97 104
Heparın plasma h2 1230 597 544 97 177
Heparın plasma h3 1251 577 342 92 109
Heparın plasma h4 1417 682 407 96 115
        Mean 96 126
        Min 92 104
        Max 97 177

Data showing dilution linearity of endogenous Periostin in human citrate plasma samples:

    Periostin [pmol/l] % Recovery
Sample matrix ID Reference 1+1 1+3 1+1 1+3
Citrate plasma c1 999 461 309 92 124
Citrate plasma c2 993 504 305 101 123
Citrate plasma c3 1079 507 328 94 122
Citrate plasma c4 1163 534 340 92 117
        Mean 95 122
        Min 92 117
        Max 101 124

Human Periostin ELISA Specificity

The specificity of an ELISA is defined as its ability to exclusively recognize the analyte of interest.

The specificity of the human Periostin ELISA was shown by characterizing both the capture and the detection antibodies through epitope mapping and affinity measurements. In addition, the specificity of the ELISA was established through competition experiments, which measure the ability of the antibodies to exclusively bind Periostin.

This assay recognizes recombinant and endogenous human Periostin.

Epitope Mapping

Antibody binding sites were determined by epitope mapping using microarray analysis (Pepperprint GmbH).

The monoclonal capture antibody was determined to bind to a linear epitope close to the N-terminus in the FAS4 domain of Periostin (AA542-549 of Q15063 (Uniprot ID), isoform 1).

The polyclonal detection antibody recognizes multiple linear epitopes distributed over the Periostin molecule (A113-121, AA125-132, AA244-250, AA694-701, AA764-771 of Q15063 (Uniprot ID), isoform 1).

A detailed description of the localization of epitops recognized by the antibodies used in this Periostin ELISA has been published:

Characterization of a sandwich ELISA for the quantification of all human periostin isoforms.
Gadermaier, E., Tesarz, M., Suciu, A.A.-M., Wallwitz, J., Berg, G., Himmler, G., 2018. J. Clin. Lab. Anal. 32 (2).
PMID: 28493527

Show Epitope Mapping

Capture Antibody:

The capture antibody, which is a monoclonal mouse antibody, binds to the sequence KGMTSEER (AA542-549 of Q15063 (Uniprot ID), isoform 1).

specificity of the human Periostin ELISA Capture Antibody

Detection Antibody:

The detection antibody, which is a polyclonal goat antibody, binds to the following AA sequences of Q15063 (Uniprot ID), isoform 1:

Epitope Sequence
1. TQRYSDASK (AA113-121)
2. EIEGKGSF (AA125-132)
3. EDDLSSF (AA244-250)
4. KTEGPTLT (AA694-701)
5. RISTGGGE (AA764-771)

specificity of the human Periostin ELISA Detection Antibody

 

Competition of Signal

Competition experiments were carried out by pre-incubating human samples containing endogenous Periostin with an excess of capture antibody (AB). The concentration measured in this mixture was then compared to a reference value, which was obtained from the same sample without the pre-incubation step. Mean competition in serum samples was 98%.

Show Individual Measurements

Periostin [pmol/l]
Sample matrixIDReferenceReference + capture AB% CompetitionSerums16471098Serums212809593Serums33720100Serums49536493Serums5144010093Serums614667695Serums7603899Serums88373396Serums94560100Serums105822100Serums114300100Serums122650100Serums134130100Serums142150100

Mean98

 

Isoforms

This assay is optimized to detect all known isoforms of human Periostin.

Cross-Reactivity

Due to the high sequence homology between human Periostin and Periostin of other species, the antibodies utilized in the assay may cross react with mouse, rat, cynomolgous monkey, dog and cat Periostin.

Sample Stability

Sample Preparation

We recommend separating plasma or serum by centrifugation as soon as possible, e.g. 20 min at 2,000 x g, preferably at 4°C (2-8°C). Samples can be stored at 4°C (2-8°C) overnight. For long term storage, aliquot the acquired plasma or serum samples and store at -25°C or lower.

Freeze-Thaw Stability

The stability of endogenous Periostin was tested by comparing Periostin measurements in samples that had undergone four freeze-thaw cycles (F/T). The mean recovery of sample concentration after four freeze-thaw cycles is 96%.

    Mean % Recovery
Sample matrix n Reference 2x F/T 3x F/T 4x F/T
Serum 4 100 100 103 98
EDTA plasma 4 100 91 93 90
Citrate plasma 4 100 93 91 97
Heparın plasma 4 100 96 96 99
        Mean 96

Samples can be subjected to four freeze-thaw cycles.

Sample Values

Serum and Plasma Periostin Values in Apparently Healthy Donors

To provide expected values for circulating Periostin, a panel of samples from apparently healthy donors was tested.

A summary of the results is shown below:

    Periostin [pmol/l]
Sample matrix n Median Range 5% percentile 95% percentile
Serum 24 864 397 – 1466 422 1439
EDTA plasma 20 817 532 – 1109 533 1105
Citrate plasma 24 885 321 – 1407 359 1357
Heparın plasma 20 891 569 – 1194 573 1192

We recommended establishing the normal range for each laboratory.

Periostin Values in Asthma and Cardiovascular Disease Panels

In addition to samples from apparently healthy donors, a panel of samples from asthma and cardiovascular disease cohorts were tested.

The results of the experiments are shown below.

Periostin Values in Asthma and Cardiovascular Disease Panels

    Periostin [pmol/l]
Cohort n Median Range 25% percentile 75% percentile
Control 18 586 165 – 840 334 666
Asthma Cohort* 10 451 241 - 1266 323 869
Cardio Cohort* 10 867 260 - 1521 663 1002

*commercially available cohort (Seralab)

Matrix Comparison

Correlation of Serum and Plasma Samples from Apparently Healthy Individuals

14 samples of apparently healthy individuals were prepared as serum and plasma pairs each deriving from one donor. Samples were assayed, and the concentrations of the samples were compared.

 

 Periostin [pmol/l]  
Sample ID Serum Citrate plasma EDTA plasma Heparın plasma CV (%)
#1 1297 1081 1243 1195 7
#2 1303 1087 1267 1345 8
#3 1710 1337 1514 1512 9
#4 1946 1775 1899 2251 9
#5 1539 1273 1392 1108 12
#6 2279 1906 2265 2316 8
#7 1901 1636 1825 1712 6
#8 1879 1678 1822 2028 7
#9 2295 1890 2026 2102 7
#10 1572 1425 1520 1760 8
#11 801 669 749 788 7
#12 1013 883 1039 806 10
#13 915 796 965 881 7
#14 941 794 992 894 8
        Mean 8
Citations

Powered by BizGenius
Reviews
Reviews
Sort by:
Submit a Review

There are no reviews yet.

Be the first to review “Human Periostin ELISA | BI-20433”

Your email address will not be published. Required fields are marked *


Downloads

Cat. No.: BI-20433

1 kit / €  675,00Please Inquire

Contact distributor

Request more information




Contact Us

Phone Head Office: +4312910711 Phone Product Support: +4312910745

Related products:

img